ArticleF&S science2026
Angiotensin II drives proliferation and extracellular matrix deposition in human uterine fibroid cells in vitro.
Article in F&S science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improved Cardiometabolic Health with Uterine-Preserving Fibroid Treatment Compared to Hysterectomy.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the effect of angiotensin II (Ang II) on proliferation and extracellular matrix (ECM) deposition in human uterine leiomyoma cells and normal myometrial cells.
designExperimental in vitro study using immortalized human leiomyoma (HuLM) cells, immortalized human uterine smooth muscle (UTSM) cells, and patient-derived primary fibroid and myometrial cells. SUBJECTS: Women with uterine fibroids who underwent hysterectomy. EXPOSURE: Administration of physiological and supraphysiological levels of Ang II (to mimic essential hypertension) to cultured HuLM, UTSM, primary fibroid, and myometrial cells to assess effects on cellular proliferation and ECM deposition.
main outcome measuresWe evaluated HuLM, UTSM, primary fibroid, and UTSM cells for the presence of the Ang II type 1 receptor. Angiotensin II-induced proliferation and ECM deposition was assessed through MTS assay, Western blot analysis, immunofluorescence, and real-time polymerase chain reaction.
resultsImmortalized and primary leiomyoma and myometrial cells expressed Ang II type 1 receptor. Leiomyoma cells responded to Ang II with increased cellular proliferation measured by MTS assay, proliferating cell nuclear antigen protein levels, and Ki67 staining. The Ang II treatment of fibroid cells showed increased expression of Collagen 1A1, the predominant fibroid and myometrial collagen. Integrin β1, an upstream regulator of fibrosis, also showed an increase in protein and messenger ribonucleic acid expression in fibroid cells treated with Ang II. No difference in proliferation or ECM production was observed in myometrial cell controls.
conclusionAngiotensin II promoted growth and matrix accumulation in fibroid cells, highlighting a potential link between fibroids and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.